Targeted Therapeutics for Cancer and Ophthalmology

At A Glance


TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. We are a leader in the field of endoglin biology and are using our expertise to develop antibodies that bind to the endoglin receptor. Our lead product candidate, TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the VEGF pathway. Our other product candidates are: DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma; TRC205, an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases; TRC253, a small molecule that is a potent, high affinity competitive inhibitor of the androgen receptor (AR) and a pan-inhibitor of multiple AR mutations, including the F876L mutation, expected to enter the clinic in 2017 for the treatment of men with prostate cancer; and TRC694, is a novel, potent, orally bioavailable inhibitor of NF-kB inducing kinase (NIK), currently in pre-clinical development for the treatment of hematologic malignancies.  

read more